Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva + Gemcitabine in First-Line Advanced NSCLC
NCT00701558Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2008
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoints: Time to Disease Progression up to 193 weeks and Overall Response Rate up to 193 weeks. Started Aug 2008; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00701558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00701558.